We treated 26 patients with 27 aneurysmal bone cysts by curettage and cryotherapy and evaluated local tumour control, complications and functional outcome. The mean follow-up time was 47 months (19 to 154). There was local recurrence in one patient. Two patients developed deep wound infections and one had a postoperative fracture.

We compared our results with previous reports in which several different methods of treatment had been used and concluded that curettage with adjuvant cryotherapy had similar results to those of marginal resection, and that no major bony reconstruction was required.

We recommend the use of cryotherapy as an adjuvant to the surgical treatment of aneurysmal bone cysts. It provides local tumour control. Combination with bone grafting achieved consolidation of the lesion in all our patients.

Received 16 July 1996; Accepted 9 September 1996

Aneurysmal bone cyst is a rare benign tumour-like lesion of bone of unknown origin. There is controversy as to whether it is a distinct radiological and pathological entity or a pathophysiological change superimposed on a pre-existing lesion. Lack of understanding about its origin and growth makes treatment empirical. The most common treatment has been curettage with bone grafting which has a substantial rate of recurrence. Lower recurrence rates can be achieved by marginal or wide resection, but are accompanied by loss of bone and the need for reconstruction. Intralesional resection or curettage with effective adjuvant therapy to extend the surgical margin has been advocated. Since 1969 we have used cryotherapy as an adjuvant after intralesional resection and we now evaluate our results.

PATIENTS AND METHODS

We performed a retrospective study of all patients treated for aneurysmal bone cyst between 1969 and 1995. This included review of all patient records, radiographs and pathology reports. The diagnosis had been made on both radiological and histological examination. Only patients with the diagnosis of aneurysmal bone cyst and no other abnormal histological findings were included.

There were 12 females and 14 males (27 aneurysmal bone cysts). The mean age at which cryotherapy was first performed was 21.7 years (4.2 to 49.6) and the distribution is shown in Table I. The bones involved are shown in Table II.

All had been treated by curettage and cryotherapy. Age, gender, history, anatomical location, tissue pathology, complications, function after surgery and length of follow-up had been recorded. Staging was accomplished using the radiological criteria for benign lesions of bone defined by Enneking.

Operative treatment consisted of intralesional resection (curettage) after bony fenestration, followed by cryotherapy. Initially, this had been used by one (2 cases), two (4 cases) or three (2 cases) freeze-thaw cycles, pouring liquid nitrogen into the bony cavity. In the subsequent 19 cases, we used three cycles of freezing and spontaneous thawing with a machine which produced a liquid nitrogen spray. The progress of freezing was usually monitored by thermocouples. A temperature of less than -50°C inside the cavity was considered to be lethal for remaining tumour cells. A thermocouple outside the cavity, preferably close to the neurovascular bundle, was used to prevent freezing of these structures. In many cases the cavity was filled with an autograft (4) or allograft (14) of bone. Spondylodesis was performed once. Preoperative antibiotic prophylaxis was used in all patients (Kefzol; Eli Lilly Nederland BV, Nieu-
Table I. Details of studies on aneurysmal bone cysts

<table>
<thead>
<tr>
<th>Authors</th>
<th>Number</th>
<th>Male</th>
<th>Female</th>
<th>Age (yrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 to 10</td>
</tr>
<tr>
<td>Campanacci et al              2</td>
<td>198</td>
<td>83</td>
<td>115</td>
<td>63</td>
</tr>
<tr>
<td>Koskinen et al</td>
<td>20</td>
<td>13</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Martinez and Sissons           12</td>
<td>87</td>
<td>45</td>
<td>42</td>
<td>25</td>
</tr>
<tr>
<td>Morton</td>
<td>26</td>
<td>14</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Nobler et al</td>
<td>33</td>
<td>13</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Ruiter et al</td>
<td>105</td>
<td>46</td>
<td>59</td>
<td>39</td>
</tr>
<tr>
<td>Szendri et al</td>
<td>52</td>
<td>31</td>
<td>21</td>
<td>15</td>
</tr>
<tr>
<td>Vergel De Dios et al</td>
<td>238</td>
<td>109</td>
<td>129</td>
<td>57</td>
</tr>
<tr>
<td>Schreuder et al</td>
<td>26</td>
<td>14</td>
<td>12</td>
<td>5 (19%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>785</td>
<td>368</td>
<td>417</td>
<td>222 (28.3%)</td>
</tr>
</tbody>
</table>

Table II. Anatomical distribution of aneurysmal bone cysts

<table>
<thead>
<tr>
<th>Authors</th>
<th>Tibia</th>
<th>Femur</th>
<th>Vertebra</th>
<th>Pelvis</th>
<th>Humerus</th>
<th>Fibula</th>
<th>Pott</th>
<th>Hand</th>
<th>Ulna</th>
<th>Radius</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biesecker et al</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>8</td>
<td>14</td>
<td>3</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>7</td>
<td>66</td>
</tr>
<tr>
<td>Campanacci et al</td>
<td>48</td>
<td>35</td>
<td>20</td>
<td>28</td>
<td>15</td>
<td>14</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>3</td>
<td>13</td>
<td>198</td>
</tr>
<tr>
<td>Cole</td>
<td>5</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Farce et al</td>
<td>1</td>
<td>5</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Koskinen et al</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>Martinez and Sissons</td>
<td>19</td>
<td>12</td>
<td>13</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>5</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>Morton</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>26</td>
</tr>
<tr>
<td>Nobler et al</td>
<td>4</td>
<td>6</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>-</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>33</td>
</tr>
<tr>
<td>Ruiter et al</td>
<td>15</td>
<td>13</td>
<td>14</td>
<td>8</td>
<td>7</td>
<td>11</td>
<td>7</td>
<td>10</td>
<td>2</td>
<td>3</td>
<td>15</td>
<td>105</td>
</tr>
<tr>
<td>Szendri et al</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>7</td>
<td>8</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>52</td>
</tr>
<tr>
<td>Vergel De Dios et al</td>
<td>34</td>
<td>40</td>
<td>34</td>
<td>26</td>
<td>14</td>
<td>18</td>
<td>13</td>
<td>15</td>
<td>7</td>
<td>8</td>
<td>29</td>
<td>238</td>
</tr>
<tr>
<td>Schreuder et al</td>
<td>6</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>27</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>157</td>
<td>143</td>
<td>101</td>
<td>104</td>
<td>82</td>
<td>66</td>
<td>57</td>
<td>42</td>
<td>34</td>
<td>28</td>
<td>83</td>
<td>897</td>
</tr>
</tbody>
</table>

Wegein, The Netherlands).

Oclusive tourniquets were not used. Patients were not allowed to bear weight on the affected limb until there were signs of radiological consolidation.

The mean clinical follow-up was 47.4 months (19 to 154). Two patients had a follow-up of less than 24 months (19 and 22). Conventional plain radiography was used in the follow-up period. Functional assessment was performed at the most recent follow-up visit and consisted of operation-related complaints and physical examination.

RESULTS

We classified 11 aneurysmal bone cysts as aggressive and 16 as active. The presenting symptom was a pathological fracture in seven patients, pain or discomfort due to swelling in 17 and neurological symptoms in two (both of whom had vertebral lesions). There was only one local recurrence, a rate of 3.7%. This cyst had been treated with one cycle of cryotherapy using the pouring technique.

Complications included two cases of deep wound infection (7.4%). Both were successfully treated by debridement and the implantation and subsequent removal of gentamicin-PMMA beads. After a fall due to breakage of a crutch handle one patient had a femoral fracture through the treated lesion; this was treated successfully by osteosynthesis. One patient with a sacral lesion had a temporary increase in neurological symptoms which resolved within three months. All bone grafts showed progressive consolidation and incorporation. At the most recent follow-up, 24 patients had normal function of the treated limb without discomfort. One had some loss of movement at the hip and one at the ankle. All patients resumed normal daily activities.

DISCUSSION

Aneurysmal bone cyst is common in adolescents and almost half of the patients are between 10 and 21 years of age. 2,6,8,11-15 There is a slight predilection for females (Table I), and great variability in the clinical course. In most cases there is pain and swelling and sometimes a
pathological fracture. When located in the vertebral column neurological symptoms, as well as pain, are likely to be present. Aneurysmal bone cysts can occur in any bone, but are more common in the metaphyses of the long bones, especially around the knee, and in the vertebral column (Table II). The demographic characteristics of our series do not differ significantly from the typical picture reported in the literature.

Aneurysmal bone cysts both erode and cause ‘expansion’ of underlying cancellous and cortical bone. Around the lesion there is always a shell formed by periosteal new bone and, although this may be only millimetres thick, it prevents direct extension into the soft tissues.16

The concept of aneurysmal bone cyst as a secondary phenomenon occurring in a pre-existing lesion is based on the fact that in approximately one-third of the cases a pre-existing lesion can be identified, the most common of which is giant-cell tumour.1 Others are osteoblastoma, angioma and chondroblastoma.1,12,17 Less common associations include fibrous dysplasia, non-ossifying fibroma, chondromyxoid fibroma, solitary bone cyst, fibrous histiocytoma, eosi

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Table III. Different types of treatment and recurrence rates of aneurysmal bone cysts

<table>
<thead>
<tr>
<th>Authors</th>
<th>Irradiation</th>
<th>Curettage + Irradiation</th>
<th>Curettage + Bonegraft</th>
<th>Curettage + Cryobiopsy</th>
<th>Marginal Resection</th>
<th>Wide Resection</th>
<th>Mean Follow-up (mth)</th>
<th>Time to First Recurrence (mth)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruiter et al6</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>&gt;24</td>
</tr>
<tr>
<td>Slowick et al21</td>
<td>4</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>83</td>
</tr>
<tr>
<td>Szendro et al8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>&gt;24</td>
</tr>
<tr>
<td>Vergel De Dios et al15</td>
<td>1</td>
<td>0</td>
<td>12</td>
<td>2</td>
<td>124</td>
<td>27</td>
<td>17</td>
<td>&gt;24</td>
</tr>
<tr>
<td>Schreuder et al</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>47</td>
<td>36</td>
</tr>
<tr>
<td>Total</td>
<td>34</td>
<td>4</td>
<td>35</td>
<td>5</td>
<td>124</td>
<td>27</td>
<td>10%</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Recurrence rates (%)</td>
<td>11.8</td>
<td>14.2</td>
<td>30.8</td>
<td>12.8</td>
<td>7.4</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table III. Different types of treatment and recurrence rates of aneurysmal bone cysts

The concept of aneurysmal bone cyst as a secondary phenomenon occurring in a pre-existing lesion is based on the fact that in approximately one-third of the cases a pre-existing lesion can be identified, the most common of which is giant-cell tumour. Others are osteoblastoma, angioma and chondroblastoma.1,12,17 Less common associations include fibrous dysplasia, non-ossifying fibroma, chondromyxoid fibroma, solitary bone cyst, fibrous histiocytoma, eosinophilic granuloma, radiation osteitis and trauma. Malignant lesions, such as osteosarcoma (especially telangiectatic), fibrosarcoma and metastatic carcinoma may have similar radiological and histological features to aneurysmal bone cysts, so accurate diagnosis is essential before advising treatment.

We agree with the view that aneurysmal bone cyst is an entity on its own having unique clinical, radiological and diagnostic behaviour. The diagnosis should be made only after the exclusion of an underlying lesion which can produce similar features. Such other conditions should be labelled after their principal element with the added description ‘cystic or haemorrhagic changes’.2 Our study included only primary aneurysmal bone cysts with no other histological findings.

Because of this lack of understanding about the origin and growth of aneurysmal bone cysts a variety of treatments has been described. They include irradiation alone, or a primary surgical approach with or without some kind of adjuvant treatment. Theoretically, adjuvant therapy may consist of systemic chemotherapy, radiotherapy and physical adjuvants like phenol, hypertonic saline merthiolate, polymethylmethacrylate (PMMA) cement applied locally, and cryotherapy.

Chemotherapy and irradiation therapy have an effect on mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

We agree with the view that aneurysmal bone cyst is an entity on its own having unique clinical, radiological and diagnostic behaviour. The diagnosis should be made only after the exclusion of an underlying lesion which can produce similar features. Such other conditions should be labelled after their principal element with the added description ‘cystic or haemorrhagic changes’.2 Our study included only primary aneurysmal bone cysts with no other histological findings.

Because of this lack of understanding about the origin and growth of aneurysmal bone cysts a variety of treatments has been described. They include irradiation alone, or a primary surgical approach with or without some kind of adjuvant treatment. Theoretically, adjuvant therapy may consist of systemic chemotherapy, radiotherapy and physical adjuvants like phenol, hypertonic saline merthiolate, polymethylmethacrylate (PMMA) cement applied locally, and cryotherapy.

Chemotherapy and irradiation therapy have an effect on mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.

Phenol is a non-selective cytotoxic agent and when applied directly to the surface of curetted tumours, it kills mitotically-active cells. Their influence on a benign lesion such as aneurysmal bone cyst is limited and we believe that they are inappropriate because of the side-effects. Although radiation therapy has been used, especially in sites of difficult surgical access, with good results (Table III), we do not advise it because of the risk of secondary sarcoma in the irradiated field.
Fig. 1

Initial anteroposterior (A) and lateral (B) radiographs of an aneurysmal bone cyst in the proximal metaphysis of the left humerus of a four-year-old boy three months after curettage, cryotherapy and bone allograft (C and D). One (E and F) and four years (G and H) later the bone has completely remodelled and the appearance of the intramedullary space is almost normal.
The rationale of the use of PMMA cement as adjuvant treatment is based on its heating effect. Experiments have shown that a thermal lesion of at least 50°C is necessary for a cytotoxic effect. The maximum peripheral extent of a thermal lesion varies from 2.5 mm in cancellous to 0.5 mm in cortical bone.24 For local control of giant-cell tumours good results with recurrence rates of 5% to 15% have been reported,24,25 but no results are available for the use of PMMA cement as adjuvant treatment of aneurysmal bone cysts.

The most commonly used treatments and their recurrence rates are summarised in Table III. The recurrence rates for irradiation with or without curettage are similar, 11.8% and 13.8% respectively. Curettage with or without bone grafting is accompanied by a high recurrence rate of 30.8%. Cryotherapy as an adjuvant after curettage has a recurrence rate of 12.8%. Marginal and wide resection are associated with low rates, 7.4% and 0% respectively. In a review of 65 cases of aneurysmal bone cysts in the facial region,26 curettage was associated with a recurrence rate of 33%, about the same as for non-facial lesions.

Cryotherapy using liquid nitrogen has been used for the treatment of benign stage-2 (active), stage-3 (aggressive) and low-grade malignant stage IA skeletal tumours.27-30 It is often advocated to avoid extensive surgical destruction of tissue.26-30 Intralesional resection is performed by curettage. Adjuvant treatment is currently given by spraying liquid nitrogen into the bony cavity. This method must be considered marginal by oncologic principles.10 The advantage, compared with local resection, is that the supportive function of bone is preserved and reconstructive surgery can be limited. In studies on the extent of the effect of freezing on bone segments in vivo, Gage31 found that the temperature gradient was steep and that at approximately 2 cm from the freezing source no freezing of bone occurred, even after 15 minutes. All the frozen bone was devitalised within one week. Osteogenesis originating from normal bone and periosteum adjacent to the frozen segment, however, was seen within several days. Revitalisation by simultaneous resorption and reossification took several months.31,32 The minimum temperature necessary for a cytotoxic effect on invasive cancer cells is believed to be -50°C to -60°C.33 Rapid cooling (more than 100°C/min) and slow thawing (1°C to 10°C/min) allows the highest cell death rates.32,34 The freeze and thaw cycles must be repeated several times because living tissue is able to resist thermal injury and it is technically difficult to achieve optimal conditions for cell death in all areas of the lesions. To compensate, repetition of freeze and thaw cycles is a practical solution and is safe especially at the periphery of the lesion.34-36 In the early days of cryotherapeutic liquid nitrogen was poured directly into a curretted tumour cavity.28 We prefer spraying liquid nitrogen, in every direction needed, because it increases the contact area of the coolant with the irregular walls of the cavity, and the freezing process is more easily controlled.

Although the cryotherapeutic technique and its potential benefits have been known for a long time, it is infrequently adopted in orthopaedic practice. This is probably due to the high incidence of complications, especially postoperative fractures and wound infections, that have been reported.26,28 Among our patients there was one postoperative fracture due to trauma. There were two deep infections which needed additional surgery. We do not use tourniquets, in order to keep nerves and skin vascularised and thereby protect them from freezing injury. Nerve injuries appear to recover completely. Gas embolism is possible, and there has been one reported mortality.29,37 The complication rate becomes less as experience with cryotherapy increases.27

We found that cryotherapy as an adjuvant to curettage of aneurysmal bone cysts is associated with a local recurrence rate of 4%. The only recurrence we had was probably due to technique as only one cycle of cryotherapy had been used. Marcove et al5 reported a recurrence rate of 18% which after additional treatments with the same technique decreased to 4%. Marginal and wide resection of aneurysmal bone cysts lead to comparable local control, but more extensive reconstructive surgery is then needed, with associated morbidity. In general, we recommend the use of cryotherapy as an adjuvant to curettage for the treatment of aneurysmal bone cysts (Fig. 1). The use of a bone graft allowed for consolidation in all cases. In expendable bones (e.g. proximal fibula, ribs) marginal resection appears to be sufficient.2 Superselective embolisation with or without irradiation may be considered for aneurysmal bone cysts located in anatomical positions which are very difficult to treat surgically, like vertebral and sacral lesions.2,8,14

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

REFERENCES

ANEURYSMAL BONE CYSTS TREATED BY CURETTAGE, CRYOTHERAPY AND BONE GRAFTING